Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center
Abstract Background Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glo...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2020-11, Vol.41 (Supplement_2) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_2 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 41 |
| creator | Milani, P Obici, L Mussinelli, R Basset, M Manfrinato, G Nuvolone, M De Matteis, G Sabena, A Benigna, F Cavenaghi, G Foli, A Perlini, S Merlini, G Palladini, G |
| description | Abstract
Background
Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations.
Objective
To describe the natural history of the disease in a large, prospective, national series.
Methods
Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019).
Results
The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P |
| doi_str_mv | 10.1093/ehjci/ehaa946.2144 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_2144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.2144</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.2144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c814-ae76d2961bf69e650fe655afc5ec25af8e858451fabcb87340c23e314e85d0ce3</originalsourceid><addsrcrecordid>eNqNkM1qwzAQhEVpoWnaF-hpj-3BqWRLit1bCP0JBArFh97MRl4RBSc2ktLgY9-8TpMH6GUGlpll-Bi7F3wieJE90Xpj3KCIhdSTVEh5wUZCpWlSaKku2YiLQiVa51_X7CaEDec810KP2M8cfe3QQPS4C3Hde4puBwfX1EnsOwLc9k3r6ja4AA-zsvw8xMdnQOh8Gzoy0X0ThLive2gtSM6hw-hoFwPYtmnaA9WAEeKaYBGxcbgDT5a8xwbMECN_y64sNoHuzj5m5etLOX9Plh9vi_lsmZhcyARpquu00GJldUFacTuIQmsUmXTwnHKVSyUsrswqn2aSmzSjTMjhXnND2Zilp7dmGB6GDVXn3RZ9XwleHRlWfwyrM8PqyHAoJadSu-_-k_8FOvp5Ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Milani, P ; Obici, L ; Mussinelli, R ; Basset, M ; Manfrinato, G ; Nuvolone, M ; De Matteis, G ; Sabena, A ; Benigna, F ; Cavenaghi, G ; Foli, A ; Perlini, S ; Merlini, G ; Palladini, G</creator><creatorcontrib>Milani, P ; Obici, L ; Mussinelli, R ; Basset, M ; Manfrinato, G ; Nuvolone, M ; De Matteis, G ; Sabena, A ; Benigna, F ; Cavenaghi, G ; Foli, A ; Perlini, S ; Merlini, G ; Palladini, G</creatorcontrib><description>Abstract
Background
Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations.
Objective
To describe the natural history of the disease in a large, prospective, national series.
Methods
Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019).
Results
The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P<0.001). The UK staging system (NT-proBNP 3000 ng/L and eGFR 45 mL/min), discriminated three groups [stage I: 170 (45%), stage II: 165 (43%) and stage III: 45 (12%)] with a significant difference in survival: between stage I and stage II (86 vs. 52 months, P<0.001) and between stage II and stage III (median survival 52 vs. 33 months, P=0.045).
Conclusions
This is one of the largest series of patients with cardiac ATTRwt reported so far. Referrals and diagnoses increased exponentially in recent years, One-third of patients has a concomitant monoclonal gammopathy and needed tissue typing. Both the current staging systems offered good discrimination of staging and were validated in our independent cohort.
Funding Acknowledgement
Type of funding source: None</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.2144</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Milani, P</creatorcontrib><creatorcontrib>Obici, L</creatorcontrib><creatorcontrib>Mussinelli, R</creatorcontrib><creatorcontrib>Basset, M</creatorcontrib><creatorcontrib>Manfrinato, G</creatorcontrib><creatorcontrib>Nuvolone, M</creatorcontrib><creatorcontrib>De Matteis, G</creatorcontrib><creatorcontrib>Sabena, A</creatorcontrib><creatorcontrib>Benigna, F</creatorcontrib><creatorcontrib>Cavenaghi, G</creatorcontrib><creatorcontrib>Foli, A</creatorcontrib><creatorcontrib>Perlini, S</creatorcontrib><creatorcontrib>Merlini, G</creatorcontrib><creatorcontrib>Palladini, G</creatorcontrib><title>Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center</title><title>European heart journal</title><description>Abstract
Background
Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations.
Objective
To describe the natural history of the disease in a large, prospective, national series.
Methods
Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019).
Results
The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P<0.001). The UK staging system (NT-proBNP 3000 ng/L and eGFR 45 mL/min), discriminated three groups [stage I: 170 (45%), stage II: 165 (43%) and stage III: 45 (12%)] with a significant difference in survival: between stage I and stage II (86 vs. 52 months, P<0.001) and between stage II and stage III (median survival 52 vs. 33 months, P=0.045).
Conclusions
This is one of the largest series of patients with cardiac ATTRwt reported so far. Referrals and diagnoses increased exponentially in recent years, One-third of patients has a concomitant monoclonal gammopathy and needed tissue typing. Both the current staging systems offered good discrimination of staging and were validated in our independent cohort.
Funding Acknowledgement
Type of funding source: None</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkM1qwzAQhEVpoWnaF-hpj-3BqWRLit1bCP0JBArFh97MRl4RBSc2ktLgY9-8TpMH6GUGlpll-Bi7F3wieJE90Xpj3KCIhdSTVEh5wUZCpWlSaKku2YiLQiVa51_X7CaEDec810KP2M8cfe3QQPS4C3Hde4puBwfX1EnsOwLc9k3r6ja4AA-zsvw8xMdnQOh8Gzoy0X0ThLive2gtSM6hw-hoFwPYtmnaA9WAEeKaYBGxcbgDT5a8xwbMECN_y64sNoHuzj5m5etLOX9Plh9vi_lsmZhcyARpquu00GJldUFacTuIQmsUmXTwnHKVSyUsrswqn2aSmzSjTMjhXnND2Zilp7dmGB6GDVXn3RZ9XwleHRlWfwyrM8PqyHAoJadSu-_-k_8FOvp5Ew</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Milani, P</creator><creator>Obici, L</creator><creator>Mussinelli, R</creator><creator>Basset, M</creator><creator>Manfrinato, G</creator><creator>Nuvolone, M</creator><creator>De Matteis, G</creator><creator>Sabena, A</creator><creator>Benigna, F</creator><creator>Cavenaghi, G</creator><creator>Foli, A</creator><creator>Perlini, S</creator><creator>Merlini, G</creator><creator>Palladini, G</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center</title><author>Milani, P ; Obici, L ; Mussinelli, R ; Basset, M ; Manfrinato, G ; Nuvolone, M ; De Matteis, G ; Sabena, A ; Benigna, F ; Cavenaghi, G ; Foli, A ; Perlini, S ; Merlini, G ; Palladini, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c814-ae76d2961bf69e650fe655afc5ec25af8e858451fabcb87340c23e314e85d0ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Milani, P</creatorcontrib><creatorcontrib>Obici, L</creatorcontrib><creatorcontrib>Mussinelli, R</creatorcontrib><creatorcontrib>Basset, M</creatorcontrib><creatorcontrib>Manfrinato, G</creatorcontrib><creatorcontrib>Nuvolone, M</creatorcontrib><creatorcontrib>De Matteis, G</creatorcontrib><creatorcontrib>Sabena, A</creatorcontrib><creatorcontrib>Benigna, F</creatorcontrib><creatorcontrib>Cavenaghi, G</creatorcontrib><creatorcontrib>Foli, A</creatorcontrib><creatorcontrib>Perlini, S</creatorcontrib><creatorcontrib>Merlini, G</creatorcontrib><creatorcontrib>Palladini, G</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Milani, P</au><au>Obici, L</au><au>Mussinelli, R</au><au>Basset, M</au><au>Manfrinato, G</au><au>Nuvolone, M</au><au>De Matteis, G</au><au>Sabena, A</au><au>Benigna, F</au><au>Cavenaghi, G</au><au>Foli, A</au><au>Perlini, S</au><au>Merlini, G</au><au>Palladini, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Background
Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations.
Objective
To describe the natural history of the disease in a large, prospective, national series.
Methods
Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019).
Results
The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P<0.001). The UK staging system (NT-proBNP 3000 ng/L and eGFR 45 mL/min), discriminated three groups [stage I: 170 (45%), stage II: 165 (43%) and stage III: 45 (12%)] with a significant difference in survival: between stage I and stage II (86 vs. 52 months, P<0.001) and between stage II and stage III (median survival 52 vs. 33 months, P=0.045).
Conclusions
This is one of the largest series of patients with cardiac ATTRwt reported so far. Referrals and diagnoses increased exponentially in recent years, One-third of patients has a concomitant monoclonal gammopathy and needed tissue typing. Both the current staging systems offered good discrimination of staging and were validated in our independent cohort.
Funding Acknowledgement
Type of funding source: None</abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.2144</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2020-11, Vol.41 (Supplement_2) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ehjci_ehaa946_2144 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| title | Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T08%3A23%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20transthyretin%20wild-type%20amyloidosis%20(ATTRwt):%20a%20prospective%20study%20of%20400%20patients%20followed%20at%20the%20Italian%20referral%20center&rft.jtitle=European%20heart%20journal&rft.au=Milani,%20P&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.2144&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.2144%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.2144&rfr_iscdi=true |